英文名稱 | Rebastinib (DCC-2036) |
---|---|
中文名稱 | Rebastinib (DCC-2036) |
CAS號(hào) | 1020172-07-9 |
分子式 | C30H28FN7O3 |
分子量 | 553.59 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
5 mg | 3-5days | ¥620.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥1000.00 | 登錄后可見(jiàn) | |
25 mg | 3-5days | ¥1800.00 | 登錄后可見(jiàn) |
英文名稱 | Rebastinib (DCC-2036) |
---|---|
中文名稱 | Rebastinib (DCC-2036) |
CAS號(hào) | 1020172-07-9 |
分子式 | C30H28FN7O3 |
分子量 | 553.59 |
外觀 | White to off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Rebastinib (formerly also known as DCC-2036), a novel, potent and orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity, is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50s of 0.8 nM and 4 nM. It also inhibits other kinases such as SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and has low activity towards c-Kit. DCC-2036 inhibits ABL1 through forcing the kinase domains into inhibitor-bound, inactive Type II conformations. In cellular assay, DCC-2036 inhibits the proliferation of Ba/F3 and K562 cells with IC50 values of 5.4nM and 5.5nM, respectively.